(Il Sole 24 Ore Radiocor) - Milano, 14 nov - The US pharmaceutical group Merck said that it has entered an agreement to buy Cidara Therapeutics for 221.50 dollars per share in cash, resulting in a total transaction value of approximately 9.2 billion dollars.

'We continue to execute our science-led business development strategy, augmenting our pipeline with CD388, a potentially first-in-class, long-acting antiviral designed to prevent influenza in individuals at higher risk of complications,' said Robert Davis, Merck's chairman and chief executive officer. 'We intend to build on the Cidara team's remarkable progress and are confident that CD388 has the potential to be another important driver of growth through the next decade, creating real value for shareholders.' The transaction is expected to close in the first quarter of.

2026, Merck added.

(RADIOCOR) 14-11-25 13:14:49 (0348) 5 NNNN